3-rx.comCustomer Support
3-rx.com
   
HomeAbout UsFAQContactHelp
News Center
Health Centers
Medical Encyclopedia
Drugs & Medications
Diseases & Conditions
Medical Symptoms
Med. Tests & Exams
Surgery & Procedures
Injuries & Wounds
Diet & Nutrition
Special Topics



\"$alt_text\"');"); } else { echo"\"$alt_text\""; } ?>


Join our Mailing List





Syndicate

You are here : 3-RX.com > Home > Bowel Problems -

New Ways To Ease Liver Disease

Bowel ProblemsSep 22, 05

Many patients with liver diseases often encounter difficulties with therapy and ultimately require liver transplant to survive. Since many acute and chronic liver diseases are driven by immune-mediated mechanisms, there is a necessity to find new therapies that can inhibit these immune-based triggers and block liver damage. In a study appearing online on March 3 in advance of publication in the April 1 print edition of the Journal of Clinical Investigation, Christian Trautwein, Christian Klein, and colleagues from Hannover Medical School identify new therapeutic targets in liver diseases.

There has been growing evidence that IL-6 is protective against many pathophysiological conditions in the liver. IL-6 is a protein called a cytokine, which has cell protective functions. In cells, IL-6 acts by binding to a specific receptor in the cell membrane, which then triggers activation of gp130, a signal transducing protein. Gp130 leads to the activation of a signaling pathway inside cells from the membrane to the nucleus called the Jak/Stat pathway.

The researchers used rodent models of liver damage that causes hepatitis and liver damage involving immune T cells. Their aim was to characterize mechanisms involved in mediating IL-6-??“dependent protection. They demonstrate that IL-6/gp130/Stat3??“dependent expression of two proteins in liver cells ??“ KC and SAA2 ??“ is essential in mediating the protective effect of IL-6.

This establishes the role of key protective factors in liver injury mediated by hepatitis and immune mechanisms. KC and SAA2 are two proteins that may be of interest in developing therapies to treat immune-mediated liver disease in humans.

###

This story has been adapted from a news release issued by Journal Of Clinical Investigation.



Print Version
Tell-a-Friend
comments powered by Disqus

RELATED ARTICLES:
  Anxiety increases the risk of gastrointestinal infection and long-term complications
  Baclofen shows promise in patients with alcohol-induced liver disease
  Mayo Clinic Proceedings: Review of pain management practices for cirrhosis patients
  Vitamin D deficiency common in patients with IBD, chronic liver disease
  Highly Acidic Beverages Not a Threat to Gastrointestinal Tracts
  How to manage Chinese obese children with non-alcoholic fatty liver disease?
  How does P wave dispersion change in patients with Wilson’s disease?
  Real-time Imaging Device May Improve Surgery for Congenital Colon Disease
  Screening probably caused cystic fibrosis drop
  U of I study: exercise to avoid gallstones!
  Talk Therapy Can Help Kids With Chronic Stomach Pain
  Chronic Fatigue Syndrome and Morning Cortisol Response

 












Home | About Us | FAQ | Contact | Advertising Policy | Privacy Policy | Bookmark Site